Substance
ID:394
Names and Identifiers
Brand Name
AcylanidCrystodiginAcigoxin
IUPAC name
(2R,3R,4S,6S)-3-hydroxy-6-{[(2R,4S,6S)-4-hydroxy-6-{[(2R,3S,4S,6R)-4-hydroxy-6-{[(1S,2S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl acetate
Synonyms
Acetyldigitoxin
IUPAC Traditional name
digitoxin, monoacetate
Registration numbers
CAS Number
Properties
Physical Property
Hydrophobicity(logP)
3.7
Solubility
0.0274 mg/L at 25 oC [MEYLAN,WM et al. (1996)]
Molecule Details
Drug Groups
approved
Description
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Indication
Used for fast digitalization in congestive heart failure.
Pharmacology
The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na+/K+ ATPase pump.
Toxicity
Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Affected Organisms
Humans and other mammals
Absorption
Bioavailability is 60 to 80% following oral administration.
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data